A restrospective study of Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) in patients with metastatic colorectal cancer
Latest Information Update: 06 Jan 2022
At a glance
- Drugs Regorafenib (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
Most Recent Events
- 01 Dec 2021 Results published in the Oncologist
- 20 Feb 2019 New trial record
- 19 Jan 2019 Results presented at the 2019 Gastrointestinal Cancers Symposium